CG Oncology, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is based in Irvine, California.

CG Oncology, Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Olema Pharmaceuticals (OLMA) and CG Oncology, Inc. (CGON). Olema ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Olema Pharmaceuticals (OLMA) and CG Oncology, Inc. (CGON)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CG Oncology, Inc. (CGON) and Spyre Therapeutics (SYR...

Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Spyre Therapeutics (SYRE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD), ProKidney (PROK) and CG Oncology, Inc. (CGON). In...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), ProKidney (PROK) and CG Oncology, Inc. (CGON)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on CG Oncology, Inc. today and set a price target of $108.00. Slutsky covers the Health...

CG Oncology, Inc. (CGON) Receives a Rating Update from a Top Analyst

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zevra Therapeutics (ZVRA), CG Oncology, Inc. (CGON) ...

Analysts Are Bullish on These Healthcare Stocks: Zevra Therapeutics (ZVRA), CG Oncology, Inc. (CGON)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CG Oncology, Inc. (CGON), Evolus (EOLS) and Nuvation...

Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on NeoGenomics (NEO), CG Oncology, Inc. (CGON) and Icon (ICLR). NeoG...

Current Quarter	$-0.7	Next Quarter	$-0.77
Current Year	$-2.89	Next Year	$-2.74
QoQ Growth	-10.0%	YoY Growth	+5.2%
3Y EPS CAGR	-47.5%	Target Price	$90.29
Consensus	Buy	Upside	+45.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CGON	$61.89	-3.67%	1.70M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CGON	$61.89	-3.7%	1.70M
3
4
5
6

CGON

CGON

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get CG Oncology, Inc. Data in Excel

Get CG Oncology, Inc. Data in Excel